Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Ju Seok Ryu
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02180880CT.gov Symptom Based Treatment of Neuropathic Pain | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Spinal Cord Injury
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxcarbazepine (this asset) | Ju Seok Ryu | Approved | B · 60 |
| Pregabalin | Ju Seok Ryu | P4 | BBB |
| Gabapentin | MetroHealth Medical Center | P4 | BB |
| VENLOR | University of Washington | P4 | BB |
| Semaglutide | James J. Peters Veterans Affairs Medical Center | P4 | BB |
| Brivaracetam | University of Minnesota | P3 | BB |
| Amitriptyline | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | P4 | BB |
| Nabilone | Eldon Loh, MD | P3 | BB |
| Lidocaine | University of Texas Rio Grande Valley | P2 | BB |
+34 more in the Spinal Cord Injury cohort
Other indications for Oxcarbazepine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Focal Epilepsy | — | P4 | BBB · 76 |
| Epilepsy | — | P4 | BB · 68 |
| Peripheral Neuropathy | — | P4 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxcarbazepine in Spinal Cord Injury. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxcarbazepine-spinal-cord-injury
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →